Genmab A/S logo

GMAB

Genmab A/S

$37.12

Earnings Summary

Revenue
$681.01Mn
Net Profits
$198.57Mn
Net Profit Margins
29.16%

Highlights

Revenue:

Genmab A/S’s revenue jumped 171.56% since last year same period to $681.01Mn in the Q1 2018. On a quarterly growth basis, Genmab A/S has generated -33.09% fall in its revenue since last 3-months.

Net Profits:

Genmab A/S’s net profit jumped 1133.46% since last year same period to $198.57Mn in the Q1 2018. On a quarterly growth basis, Genmab A/S has generated -74.73% fall in its net profits since last 3-months.

Net Profit Margins:

Genmab A/S’s net profit margin jumped 354.21% since last year same period to 29.16% in the Q1 2018. On a quarterly growth basis, Genmab A/S has generated -62.23% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Genmab A/S post its latest quarter earnings

EPS Estimate Current Quarter
0.13
EPS Estimate Current Year
0.13

Highlights

EPS Estimate Current Quarter:

Genmab A/S’s earning per share (EPS) estimates for the current quarter stand at 0.13 - a -64.13% fall from last quarter’s estimates.

EPS Estimate Current Year:

Genmab A/S’s earning per share (EPS) estimates for the current year stand at 0.13.

Key Ratios

Key ratios of the Genmab A/S post its Q1 2023 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Genmab A/S’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the Genmab A/S has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2019-12-31
3.43
3.41
-0.58%
2019-06-30
0.27
0.2
-25.93%
2019-09-30
0.36
1.23
241.67%

Company Information

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.

Organisation
Genmab A/S
Headquarters
Kalvebod Brygge 43, Copenhagen, Denmark, 1560
Employees
1660
Industry
Health Technology
CEO
Jan van de Winkel